Sign inJoin waitlistJoin the waitlist

DA

Danielle Antin-Ozerkis

Medical Director, Yale ILD Center of Excellence, Pulmonary, Critical Care & Sleep Medicine · Yale School of Medicine

Credentials: · · ·

History

Yale ILD Center of Excellence · Yale School of Medicine
Present
Yale ILD Center of Excellence · Yale School of Medicine
Present
Yale School of Medicine
Present

University of Pennsylvania Health System
Until 2006
University of Pennsylvania
University of Pennsylvania
Until 2002
University of Pennsylvania Medical School
1999
Princeton University
1990

Research

Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review
Review · Clinical Cancer Research · 2005 · 244 citations
Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype
Laboratory Investigation · 2010 · 191 citations
Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial
JAMA · 2018 · 189 citations

Erica Herzog
5 papers
Jonathan Chung
5 papers
Mary Scholand
5 papers · 5 as a resident
Monique Hinchcliff
5 papers
Mridu Gulati
5 papers
Alicia Hinze
4 papers · 4 as a fellow
AW
Anil Warrier
4 papers
Ashima Makol
4 papers
Bradford Bemiss
4 papers
Cheilonda Johnson
4 papers
Christine Sharkey
4 papers · 4 as a resident
Didem Saygin
4 papers

Clinical trials

Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis
Principal investigator · Active not recruiting · Phase 1, Phase 2
National Jewish Health
2020–2025
Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Principal investigator · Completed · Phase 2
Kyntra Bio
2013–2017
Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF
Principal investigator · Completed · Phase 3
Duke University
2009–2014
AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis
Principal investigator · Terminated · Phase 3
Duke University
2009–2011